Gram-positive bacteria specific binding compounds

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Genentech, Inc., , Aimm Therapeutics B.V. patent solves the following problem:

Program-positive microorganisms cause many systemic infections. An important member of the gram-positive pathogens are Staphylococcus aureus (S. aureus). 20% of the population is a long-term carrier of S. aureus. S. aureus can cause a range of illnesses from minor skin infections, such as pimples, impetigo (may also be caused by streptococcus pyogenes), boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome and abscesses , life-threatening diseases such as pneumonia, meningitis, osteomyelitis, endocarditis, Toxic shock syndrome (TSS), and septicemia. S. aureus is capable of infecting all kinds of organs and tissues. S. aureus infection occur in immunocompetent as well as in immune compromised people. 50% of infections in US intensive unit care causing pathogen. Three hundred thousand S. aureus infections every year, resulting in 12,000 deaths, reported in the US (see also Moran et al. NEMJ 355, 666-674 (2006)).

Our analysis of this patent is as follows:

Genentech, Inc., , Aimm Therapeutics B.V.’s patent US 9458228 B2 deals with Gram-positive bacteria specific binding compounds.
The present invention provides improved value compounds can specifically bind gram-positive bacteria. Binding compounds which are fully human, so that therapeutic applications of human individuals.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Kits for systems and methods using acoustic radiation pressure

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Life Technologies Corporation patent solves the following problem:

Embodiments of the present invention relate to systems using acoustic radiation pressure.

Our analysis of this patent is as follows:

Life Technologies Corporation’s patent US 9457139 B2 deals with Kits for systems and methods using acoustic radiation pressure.
A kit of reagents for use in an acoustic apparatus includes a first fluid that is a lysis fluid, a second fluid having an acoustic difference greater than the first fluid, and a reagent for the calling of a particle.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Autonomous authentication of a reader by a radio frequency identity (RFID) device

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Sprint Communications Company, L.P. patent solves the following problem:

Radio frequency identity (RFID) tags are small passive devices often store a small amount of data. RFID tags usually consists of a radio transceiver and an antenna. When a proper radio frequency field is, the antenna RFID tag prompting get energy from the field of radio frequency and radio transceiver pass the data stored. RFID tags, depending on their implementation and operation specifications will be very small. RFID tags can apply to other things, and which is used for inventory control. An RFID reader or scanner device may emit the appropriate radio frequency field and reading the information broadcasted RFID tag or RFID tags located in that field RFID.

Our analysis of this patent is as follows:

Sprint Communications Company, L.P.’s patent US 9460573 B1 deals with Autonomous authentication of a reader by a radio frequency identity (RFID) device.
A radio frequency identity (RFID) tag. tag comprises a processor, a memory, which stores the memory of private information and public information, and a radio transceiver configured to receive a request for information from an RFID reader and submit a response to the request for information. The further comprise an application stored in the memory, when executed by the processor, parses a request for information from the RFID reader received radio transceiver, and determines if the RFID reader approved to receive private information. When the RFID reader determined to let the application read private information from the memory and sent to private information to the radio transceiver in passing; When the RFID reader determined not authorized, the application read the public information and public sent information to the radio transceiver in passing.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods and compositions for wound healing

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Coda Therapeutics, Inc. patent solves the following problem:

following includes information that may be helpful in understanding the present invention. This is not a claim that any of the information provided in the prior art, or relevant, now described or claimed inventions, or that any publication or document that specifically or bug- all references to prior art.

Our analysis of this patent is as follows:

Coda Therapeutics, Inc.’s patent US 9457044 B2 deals with Methods and compositions for wound healing.
Methods and compositions comprising a combination of one or more anti-connexin agents and one or more other agents useful for promotion and / or promote wound healing and / or tissue to ayo.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Filter element and filter system with a filter element

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Mann+Hummel Gmbh patent solves the following problem:

the invention of a filter element, in particular for use as an air filter in an internal combustion engine, as well as a filter system for the installation of such a filter element.

Our analysis of this patent is as follows:

Mann+Hummel Gmbh’s patent US 9457308 B2 deals with Filter element and filter system with a filter element.
A filter element having a filter body having a longitudinal axis, wherein the filter body has a first end with a first end face and a second end to a second end face opposite the first end in the direction of the longitudinal axis. The filter body provided inside and outside circumferential surfaces permeable for a medium filtered. A first end disk arranged on the first end face and a second end disk arranged on the second end face. The outer circumferential surface of the filter body has at least one fluid-tight is the place to be for the medium filtered. The fluid-tight place is a future flow protector or an improper management defender resting on the outer circumferential surface.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

ePTFE filter for aseptic pharmaceutical use and method of using

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The American Air Filter Company, Inc. patent solves the following problem:

In most aseptic pharmaceutical cleanrooms, the last step in removing airborne particles occur in a high efficiency particulate air (HEPA) or ultra-low penetration air (ULPA) filter air delivery to a controlled space. If the cleanroom attains and maintains its class designed cleanliness depends on performance of these filters. Therefore, it is a common and good practice to try to make all the filters installed in cleanrooms to ensure that they meet the design specifications. Filtering often tested during manufacture for general effectiveness and leaks. However, some cleanrooms in regulated industries, like the pharmaceutical industry, these filters are also certified each to ensure acceptable performance during their service life. Various organizational issues recommended practices for certification in Hepa and ULPA filters for filter leak test and standards for testing and classifies such filters.

Our analysis of this patent is as follows:

American Air Filter Company, Inc.’s patent US 9457301 B2 deals with ePTFE filter for aseptic pharmaceutical use and method of using.
A Hepa filter using a spun bond scrim material and ePTFE membrane for use in an aseptic pharmaceutical management and air filtration systems for installation and testing given. The installation and testing configuration includes ePTFE filter with a low or ultra-low concentration in the challenging aerosol surface of the filter with a scanning device for determining the surface concentration, all ended in situ in a pharmaceutical air handling system. At the bottom of the ePTFE filter was another scanner to be a separate piece scanner for calculating the percent penetration of the aerosol through the filter media with ultra-low concentration. The system configuration allows for exposure of ePTFE filter media for certification low or ultra-low concentrations of oil based challenging compounds.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Liquid ejection control device, liquid ejection system, and control method

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Seiko Epson Corporation patent solves the following problem:

The present invention relates to a liquid ejection control device that controls a liquid ejection device that uses a piezoelectric element and driven in a liquid having a pulsed form.

Our analysis of this patent is as follows:

Seiko Epson Corporation’s patent US 9456841 B2 deals with Liquid ejection control device, liquid ejection system, and control method.
A liquid ejection control device, an operation unit includes a momentum dial inputting the momentum that sent the value related to speed in a pulsed liquid jet ejected from a liquid ejection device, and a you repeatedly frequency dial inputting a repeated rate frequency instruction related to the number of times ejection of pulsed liquid occurs per unit of time. Furthermore, a controller includes a voltage magnitude conditions section set voltage magnitude of drive voltage waveform has such momentum was strong teaching value, based on a growing index value related to rising the drive voltage waveform has repeatedly frequency to teach values.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

PEGylation by the dock and lock (DNL) technique

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Ibc Pharmaceuticals, Inc. patent solves the following problem:

The effectiveness of a therapeutic agent may be enhanced by improving its bioavailability in some ways, one of which is the PEGylation, a process of chemically linking polyethylene glycol (PEG) to therapeutic agents of interest, with the conjugate results showed an increased serum half-life. Additional advantages of pegylated products that also include low immunogenicity, reduced dosing frequency, increased solubility, enhanced durability, and reduced renal clearance. Because the most common reactive sites on the protein (including peptide) for attaching PEG is the amino groups of lysine and the amino group of the A-terminal residue, the first method of PEGylation resulted in changes many places, yielding not only monoPEGylated conjugates consisting of mixtures of isomers seats, as PEGINTRON (Grace et al, J. Biol Chem 2005; 280: 6327) and PEGASYS (Dhalluin et al, Bioconjugate Chem 2005; 16: 504), but also adducts containing more than one PEG chain. Site-specific attachment of a PEG amino group of A-terminal residue reported that the predominant reaction products PEG-aldehyde (PEG-ALD) to lower pH of the IFN-1b (Basu et al., Bioconjugate Chem. 2006, 17: 618) or IFN-1a (Pepinsky et al, J. Pharmacol exp Father 2001; 297: …. 1059). Similar methods were applied in preparing N-ill relative PEG to G-CSF (Kinstler et al, Pharm Res 1996; 13: 996) or the soluble tumor necrosis things receptor (Kerwin et al Protein Sci 2002; 11: 1825). More recently, a strong-phase process for PEGylation A-terminus artificial interferon alpha-2a reported (Lee et al., Bioconjug. Chem. Oct. 18, 2007, ePub).

Our analysis of this patent is as follows:

Ibc Pharmaceuticals, Inc.’s patent US 9457100 B2 deals with PEGylation by the dock and lock (DNL) technique.
The present invention concerns methods and compositions for forming pegylated complexes of defined stoichiometry and structure. In preferred embodiments, the pegylated complex formed using dock-and-lock technology, by attaching a target agent to a DDD file and pasting a PEG moiety to an AD and authority DDD sequence to bind to AD in a 2: 1 stoichiometry, to form pegylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent can be included in the AD and the PEG to the DDD to form pegylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activities. The pegylated complexes exhibit a significantly slower rate of clearance when injected into a subject and the use for the treatment of a wide variety of diseases.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Internal magnetic filter for hydraulic systems

File for Quick & Easy Patent Protection with PowerPatent.

The BBB Industries LLC patent solves the following problem:

Disclosure This related to the field of hydraulic systems filtration, in particular, the filtering devices and machinery used to remove debris from the automotive power steering fluid circulating through a power steering system .

Our analysis of this patent is as follows:

BBB Industries LLC’s patent US 9457300 B2 deals with Internal magnetic filter for hydraulic systems.
A simple inlet filter elements for use primarily in the power steering column that contains a filter mesh, a magnet attached to the mesh filter and a button cap. filter to install a dock or canal through which fluid flows and directing made on the button cap element.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods for bilateral renal neuromodulation

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Medtronic Ardian Luxembourg S.A.R.L. patent solves the following problem:

Congestive Heart Failure (CHF) is a condition that occurs when the heart becomes damaged and reduces blood flow to the organs of the body. If blood flow decreases sufficiently, kidney function may change, resulting in fluid retention, abnormal hormone secretions and increased constriction of blood vessels. These results increase the work the heart and further decrease the capacity of the heart to pump blood through the kidneys and circulatory system.

Our analysis of this patent is as follows:

Medtronic Ardian Luxembourg S.A.R.L.’s patent US 9456869 B2 deals with Methods for bilateral renal neuromodulation.
Methods and apparatus provided for bilateral renal neuromodulation, for example, by a pulsed electric field, through a stimulation electric field, by local drug delivery, with high frequency ultrasound, by heat techniques, etc. the neuromodulation be permanently effectuate electroporation or electrofusion, necrosis and / or inducement of apoptosis, modification of gene expression, action potential attenuation or blockade, changes in cytokine-in-and in some cases the target nerve fibers. In some embodiments, neuromodulation applied to nerve fibers that contribute to renal function. In some embodiments, the neuromodulation made in a bilateral way. Bilateral bladder neuromodulation be enhanced therapeutic effect in some patients as compared to bladder neuromodulation made unilaterally, ie, compared to bladder neuromodulation made nervous tissue innervating a kidney.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.